Condition: Thyroid Eye Disease · Sponsor: Amgen
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Applied Research Center of Arkansas | Little Rock, Arkansas, United States | Recruiting |
| Amy Patel Jain MD | Newport Beach, California, United States | Recruiting |
| Levenson Eye Associates | Jacksonville, Florida, United States | Recruiting |
| Ilumina Medical Research | Kissimmee, Florida, United States | Recruiting |
| Sarasota Retina Institute | Sarasota, Florida, United States | Recruiting |
| Vision Medical Research, Inc. | Orland Park, Illinois, United States | Recruiting |
| Massachusetts Eye and Ear Infirmary | Boston, Massachusetts, United States | Recruiting |
| Ppd Las Vegas Research Unit | Las Vegas, Nevada, United States | Recruiting |
| Erie Retina Research | Erie, Pennsylvania, United States | Recruiting |
| Baylor College of Medicine Medical Center | Houston, Texas, United States | Recruiting |
| Consano Clinical Research, LLC | Shavano Park, Texas, United States | Recruiting |
| West Virginia University | Morgantown, West Virginia, United States | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06401044